NAMUTECH announced on the 2nd that it has signed a mutual investment and strategic business cooperation agreement with L&C Bio, a specialist in regenerative medicine for human tissues. The agreement aims for comprehensive business cooperation in the cloud and bio sectors, as well as the exploration of new growth businesses and the strengthening of product portfolios. Both NAMUTECH and L&C Bio will make mutual investments in their respective subsidiaries, L&C Medicare and Acornsoft.
Based on this partnership, the companies have agreed to jointly develop an ‘AI Healthcare Platform’ (provisional name) and cooperate in various healthcare projects. NAMUTECH will support AI and cloud technologies, while L&C Bio will contribute its pharmaceutical and healthcare market expertise and customer network to create synergies.
Chul Jung, CEO of NAMUTECH, said, “We will make every effort to facilitate broad IT cooperation using our Cocktail Cloud and AI and big data technologies, optimized for the healthcare sector.” He emphasized that combining the differentiated technologies of both companies would lead to mutual growth and the creation of sustainable future value.
Whan Chul Lee, CEO of L&C Bio, expressed, “By integrating NAMUTECH’s unique cloud platform and AI technologies with L&C Bio, we expect to be able to deliver optimized healthcare services to the medical field.”
